Market report: Biotechs up for third week in a row

By David Binning
Saturday, 27 November, 2010

The S&P/ASX 200 Heathcare Index closed in the black on Friday for the third week in a row, as the wider market slipped for the second week in a row.

It closed the week up two percent to 8665.9 points, while the benchmark S&P/ASX 200 Index fell 31.2 points to 4598.

Biotech performer of the week was Cochlear which managed a gain of eight percent to close the week on $78.75. Things weren’t so bright for the other majors, with ResMed down 47 cents to $32.18, while market leader CSL added just 27 cents to close at $35.00.

Like the broader market, volumes were also thin for biotechs on Friday.

Looking at the best and worst performers, biologics company Circadian technologies fell 8.15 percent to $0.62 while antibody specialists Patrys closed the day down 4.76 percent to $0.10.

Among the stocks heading north, biomarker and diagnostics company Healthlinx gained 6.33 percent to $0.084, while spray-on-skin specialists Avita Medical gained 4.76 percent to close Friday on $0.10.

Related News

Maternal diet doesn't affect baby's food allergy risk

Higher maternal consumption of egg and peanut during pregnancy and breastfeeding does not protect...

Overuse of inhalers can increase heart attack risk

Overuse of reliever inhalers is associated with higher risks of developing and dying from...

Unhealthy Western diet could accelerate cognitive decline

An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd